Company Overview of Yeda Research and Development Company Ltd.
Yeda Research and Development Company Ltd., a technology transfer company, markets and commercializes intellectual properties that are created in the laboratories of Weizmann Institute of Science. The company identifies and assesses research projects with commercial potential, protects the intellectual property of the institute and its scientists, licenses the institute’s inventions and technologies to industry, and channels funding from industry to research projects. It markets and commercializes intellectual properties that cover a range of natural sciences, including biotechnology, pharmaceuticals, and diagnostics; bioinformatics, proteomics, biomatics, and system biology; medical devices...
Weizman Institue of Science
de Botton Building (Building No. 5)
P.O. Box 95
Founded in 1959
Key Executives for Yeda Research and Development Company Ltd.
Chief Intellectual Property Officer
Compensation as of Fiscal Year 2015.
Yeda Research and Development Company Ltd. Key Developments
TxCell SA Enters into Exclusive Option Agreement with Yeda Research and Development
Nov 2 15
TxCell SA announced that it has entered into an exclusive option agreement with Yeda Research and Development Co. Ltd. Resulting from the exclusive option agreement, TxCell will gain exclusive access to a CAR-Treg patent for suppression of autoimmune and inflammatory diseases originated in the Weizmann Institute of Science laboratory of Professor Zelig Eshhar. The patent application under the option that TxCell has obtained covers redirected, genetically engineered T regulatory cells (CAR-Treg) and their use in suppression of autoimmune and inflammatory diseases. The option agreement grants TxCell until June 30, 2016 to opt-in at predefined terms.
Yeda Presents at BIO-Europe 2015, Nov-03-2015 02:50 PM
Oct 21 15
Yeda Presents at BIO-Europe 2015, Nov-03-2015 02:50 PM. Venue: Munich, Germany.
XTL Biopharmaceuticals Announces Agreement with Yeda Research and Development Company Ltd to Amend License
Oct 13 15
XTL Biopharmaceuticals Ltd. announced that it has reached agreement with Yeda Research and development Company Ltd. to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE). The amended agreement extends the time for achievement of key development milestones by approximately five additional months including delivery to Yeda of a full protocol for an upcoming clinical trial on hCDR1, raising an aggregate of USD 5 million and commencing a clinical trial on hCDR1 by January 2017. The amended agreement recognizes XTL's efforts to date to advance hCDR1to a clinical trial including assembling a world-class Clinical Advisory Board with leading names in SLE, strengthening the Company's Board with Directors with drug development and financial market experience, transferring the IND relating to hCDR1from Teva Pharmaceutical Industries Limited to the Company, manufacturing the drug substance for the upcoming trial, engaging in ongoing discussions with the FDA to seek opportunities to strengthen hCDR1intellectual property and optimize the regulatory pathway, and raising USD 4 million out of the aggregate amount of USD 5 million as required by the License Agreement.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries